Brian O’Reilly is an expert in the complexities of the Hatch-Waxman Act (the statute governing generic pharmaceutical patent litigation also known as ANDA law). He has represented clients in multiple Hatch-Waxman litigations and has advised numerous companies on the effect of the Hatch-Waxman Act on potential investments. He has also drafted numerous highly complex settlement agreements intertwined with and dependent on the Act.
And Brian is recognized by his colleagues as a leader in the field. Because of his expertise, and while working at the premier Hatch-Waxman law firm, he led the firm’s educational efforts related to the Hatch-Waxman statute. He was recently interviewed by IPPro Life Sciences regarding the Hatch-Waxman stuate and quoted in the October 2013 in article titled How Safe is the Harbor.
When clients and other lawyers have tough Hatch-Waxman questions, they turn to Brian.